The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use ...

Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) ...

UK MHRA grants marketing authorization to Valneva’s chikungunya vaccine, Ixchiq: Saint Herblain, France Thursday, February 6, 2025, 12:00 Hrs [IST] Valneva SE, a specialty vacci ...

The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...

Valneva (VALN) announced that the Medicines and Healthcare products Regulatory Agency or MHRA has granted marketing authorization in the United ...

Valneva has recieved Medicines and Healthcare products Regulatory Agency (MHRA) authorisation in the UK for the world’s first ...

French biotech Valneva has secured marketing approval in the UK for its chikungunya vaccine, Ixchiq (chikungunya vaccine), ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 February 2025, approved the vaccine chikungunya vaccine (live) (brand name ...

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...

The Business Research Company's Ixchiq Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase ...

Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...

Valneva has shared positive results from a late-stage study of its single-dose chikungunya vaccine in adolescents aged 12 to 17 years. The vaccine, Ixchiq, is already approved in the US, Europe and ...